Download PDF
Psychiatr Prax 2005; 32: 25-30
DOI: 10.1055/s-2004-834589
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Medikamentösinduzierte extrapyramidalmotorische Störungen: vermeiden, erkennen, behandeln

Extrapyramidal Side-Effects: Avoidance, Diagnosis and TreatmentW.  Wolfgang  Fleischhacker1 , Christian  Widschwendter1
  • 1Abteilung für Biologische Psychiatrie Universitätsklinik für Psychiatrie Innsbruck, Medizinische Universität Innsbruck
Die Autoren bedanken sich ausdrücklich bei Frau Silvia Brandl, Dr. Albert Putzhammer und Prof. Dr. Göran Hajak, die die Transkription eines von Wort gehaltenen Vortrages erstellt haben.Prof. Fleischhacker hat finanzielle Forschungsunterstützung und Honorare von folgenden Firmen erhalten: Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Organon, Otsuka, Pfizer, Sanofi-Synthelabo
Further Information

Publication History

Publication Date:
07 April 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Akute extrapyramidalmotorische Störungen (EPMS) stellen eine häufige Nebenwirkung bei antipsychotischer Behandlung dar. EPMS führen zu reduzierter Lebensqualität und zu verminderter Compliance der Patienten. Dieser Artikel gibt einen Überblick über die unterschiedlichen Formen von EPMS, stellt die Vermeidung dieser Nebenwirkungen kurz dar, zeigt Diagnose- und Behandlungsprobleme auf, und weist auf die Bedeutung von prophylaktischen Maßnahmen hin. Die Antipsychotika der neueren Generation führen im Vergleich zu klassischen Antipsychotika deutlich seltener zu EPMS, wie zahlreiche Studien zeigen. Dennoch gibt es widersprüchliche Arbeiten zu diesem Thema. Dieser Artikel diskutiert einige dieser Ergebnisse und beleuchtet auch Probleme betreffend die Methodik der Erhebung von Nebenwirkungen.

Abstract

Acute extrapyramidal side-effects (EPS) are a common phenomenon of treatment with antipsychotics. They are associated with a substantial reduction of the patient's quality of life and of compliance with the treatment. This article gives an overview of the different forms of EPS. It outlines strategies to avoid these side-effects and discusses problems in diagnosis and treatment. In comparison to conventional compounds, the clearest advantage of new generation antipsychotics is a reduced risk of the occurrence of extrapyramidal side-effects (EPS). Many studies have found that newer antipsychotics have a lesser propensity to causes EPS. Nevertheless, there are some conflicting results on this topic. This article discusses some of these results and sheds light on methodological problems in the evaluation of side-effects of antipsychotic treatment.

Literatur

  • 1 Carlson C D, Cavazzoni P A, Berg P H, Wie H, Beasley C M, Kane J M. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone or clozapine.  J Clin Psychiatry. 2003;  64 (8) 898-906
    PubMedGoogle Scholar
  • 2 Marder S R, McQuade R D, Stock E, Kaplita S, Marcus R, Safferman A Z, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerbility in short-term, placebo-controlled trials.  Schizophr Res. 2003;  61 (2 - 3) 123-136
    CrossrefPubMedGoogle Scholar
  • 3 Stanniland C, Taylor D. Tolerability of atypical antipsychotics.  Drug Saf. 2000;  22 (3) 195-214
    PubMedGoogle Scholar
  • 4 Barach E, Dubin L M, Tomlanovich M C, Kottamasu S. Dystonia presenting as upper airway obstruction.  J Emerg Med. 1989;  7 (3) 237-240
    CrossrefPubMedGoogle Scholar
  • 5 Koeck R J, Pi E H. Acute laryngeal dystonic reactions to neuroleptics.  Psychosomatics. 1989;  30 (4) 359-364
    PubMedGoogle Scholar
  • 6 Casey D. Neuroleptic side effects: Acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Cristensen AV (eds) Psychopharmacology: Current trends. Berlin; Springer-Verlag 1988: 74-93
    Google Scholar
  • 7 Green J H. Frequent rehospitalization and non-compliance with treatment.  Hosp Community Psychiatry. 1988;  39 (9) 963-966
    PubMedGoogle Scholar
  • 8 Ayd Jr F J. A survey of drug-induced extrapyramidal reactions.  JAMA. 1961;  175 1054-1060
    CrossrefPubMedGoogle Scholar
  • 9 American Psychiatric Association .Diagnostic and statistical manual of mental disordes. 4th ed. Washington DC; APA 1994
    Google Scholar
  • 10 Casey D E, Keepers G A. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Christensen AV (eds) Psychopharmacology: current trends. Berlin; Springer-Verlag 1988: 74-93
    Google Scholar
  • 11 Tarsy D, Baldessarini R J, Tarazi F I. Effects of newer antipsychotics on extrapyramidal function.  CNS Drugs. 2003;  17 (3) 202
    PubMedGoogle Scholar
  • 12 Fleischhacker W W, Lemmens P, Baelen B van. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.  Pharmacopsychiatry. 2001;  34 (3) 104-110
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Seeman P, Tol H H Van. Dopamine receptor pharmacology.  Curr Opin Neurol Neurosurg. 1993;  6 (4) 602-608
    PubMedGoogle Scholar
  • 14 World Health Organization heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness . Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement.  Br J Psychiatry. 1990;  156 412
    PubMedGoogle Scholar
  • 15 Casey D E. Motor and mental aspects of extrapyramidal syndromes.  Int Clin Psychopharmacol. 1995;  10 (Suppl 3) 105-114
    PubMedGoogle Scholar
  • 16 Keepers G A, Clappison V J, Casey D E. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.  Arch Gen Psychiatry. 1983;  40 (10) 1113-1117
    CrossrefPubMedGoogle Scholar
  • 17 Rupniak N M, Jenner P, Marsden C D. Acute dystonia induced by neuroleptic drugs.  Psychopharmacology (Berl). 1986;  88 (4) 403-419
    PubMedGoogle Scholar
  • 18 Snyder S, Greenberg D, Ymamura H I. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects.  Arch Gen Psychiatry. 1974;  31 (1) 58-61
    PubMedGoogle Scholar
  • 19 Friis T, Christensen T R, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathasia, parkinsonism and hyperkinesias. A double-blind cross-over study with placebo.  Acta Psychiatr Scand. 1983;  67 (3) 178-187
    PubMedGoogle Scholar
  • 20 Putten T Van, May P R, Marder S R. Akathisia with haloperidol and thiothixene.  Arch Gen Psychiatry. 1984;  41 (11) 1036-1039
    PubMedGoogle Scholar
  • 21 Casey D E. Motor and mental aspects of acute extrapyramidal syndromes.  Acta Psychiatr Scand Suppl. 1994;  380 14-20
    PubMedGoogle Scholar
  • 22 Miller C H, Fleischhacker W W. Managing antipsychotic-induced acute and chronic akathisia.  Drug Saf. 2000;  22 (1) 73-81
    PubMedGoogle Scholar
  • 23 Adler L A, Angrist B, Reiter S, Rotrosen J. Neuroleptic-induced akathisia: a review.  Psychopharmacology (Berl). 1989;  99 (1) 134-135
    CrossrefPubMedGoogle Scholar
  • 24 Fleischhacker W W, Miller C H, Barnas C, Bergmann K, Perovich R, Alvir J M, Lieberman J A, Kane J M. The effect of activation procedures on neuroleptic-induced akathisia.  Br J Psychiatry. 1993;  163 781-784
    PubMedGoogle Scholar
  • 25 Marsden C D, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.  Psychol Med. 1980;  10 (1) 55-72
    PubMedGoogle Scholar
  • 26 Casey D E. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates.  Psychopharmacology (Berl). 1993;  112 (Suppl 1) S55-S59
    PubMedGoogle Scholar
  • 27 Adler L A, Reiter S, Corwin J, Hernald P, Angrist B, Rotrosen J. Neuroleptic-induced akathisia - propranolol versus benztropine.  Biol Psychiatry. 1988;  23 (2) 211-213
    CrossrefPubMedGoogle Scholar
  • 28 Braude W M, Barnes T R, Gore S M. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions.  Br J Psychiatry. 1983;  143 139-150
    PubMedGoogle Scholar
  • 29 Poyurovsky M, Epshtein S, Fuchs C, Schneidmann M, Weizman R, Weizman A. Efficacy of low dose mirtazapine in neuroleptic-induced akathisia: adouble blind randomized placebo-controlled pilot study.  J Clin Psychopharmacol. 2003;  23 (3) 305-308
    CrossrefPubMedGoogle Scholar
  • 30 Barnes T R, Braude W M. Akathisia variants and tardive dyskinesia.  Arch Gen Psych. 1985;  42 (9) 874-878
    PubMedGoogle Scholar
  • 31 Casey D E. Spontaneus and tardive dyskinesias: clinical and laboratory studies.  J Clin Psychiatry. 1985;  46 (4 Pt 2) 42-47
    PubMedGoogle Scholar
  • 32 Kane J M, Jeste D V, Barnes T R. Tardive Dyskinesia: a task force report of the American Psychiatric Association. 1992
    Google Scholar
  • 33 Casey D E. Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. New York; Raven Press 1995: 1497-1502
    Google Scholar
  • 34 Gardos G, Casey D E, Cole J O, Pereni A, Kocsis E, Arato M, Samson J A, Conley C. Ten year outcome of tardive dyskinesia.  Am J Psychiatry. 1994;  151 (6) 836-841
    PubMedGoogle Scholar
  • 35 Lieberman J A, Saltz B L, Johns C A, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia.  Br J Psychiatry. 1991;  158 503-510
    PubMedGoogle Scholar
  • 36 Lohr J B, Kuczenski R, Niculescu A B. Oxidative mechanisms and tardive dyskinesia.  CNS Drugs. 2003;  17 (1) 47-62
    PubMedGoogle Scholar
  • 37 Tarsy D, Kaufman D, Sethi K D, Rivner M H, Molho E, Factor S. An open label study of botulinum toxin A for treatment of tardive dystonia.  Clin Neuropharmacol. 1997;  20 (1) 90-93
    PubMedGoogle Scholar
  • 38 Marsalek M. Tardive drug-induced extrapyramidal syndromes.  Pharmacopsychiatry. 2000;  33, Suppl 1 14-33
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical Antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.  BMJ. 2000;  321 (7273) 1371-1376
    CrossrefPubMedGoogle Scholar
  • 40 Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.  Schizophr Res. 1999;  35 (1) 51-68
    CrossrefPubMedGoogle Scholar
  • 41 Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.  Lancet. 2003;  361 (9369) 1581-1589
    CrossrefPubMedGoogle Scholar
  • 42 Miller C H, Mohr F, Unbricht D, Woerner M, Fleischhacker W W, Liebermann J A. The prevalence of extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics.  J Clin Psychiatry. 1998;  59 (2) 69-75
    PubMedGoogle Scholar
  • 43 Csernansky J G, Mahmoud R, Brenner R. Risperidone-USA-79 Study Group . A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.  N Engl J Med. 2002;  346 (1) 16-22
    CrossrefPubMedGoogle Scholar
  • 44 Tollefson G D, Kuntz A J. Review of recent clinical studies with olanzapine.  Br J Psychiatry Suppl. 1999;  174 (37) 30-35
    PubMedGoogle Scholar

W. Wolfgang Fleischhacker

Universitätsklinik für Psychiatrie Innsbruck

Anichstraße 35

6020 Innsbruck · Österreich

Email: wolfgang.fleischhacker@uibk.ac.at